|
Kinnate Biopharma Inc (NASDAQ: KNTE) |
|
Kinnate Biopharma Inc
KNTE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Kinnate Biopharma Inc 's sales fell
in III. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Kinnate Biopharma Inc net loss decreased from $-31 millions, to $-31 millions in III. Quarter 2023,
• More on KNTE's Growth
|
|
Kinnate Biopharma Inc realized a net loss in trailing twelve months.
Kinnate Biopharma Inc realized cash reduction of $ -0.2 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
• More on KNTE's Valuation
|
|
|
|
|
Kinnate Biopharma Inc realized net loss in trailing twelve months.
Kinnate Biopharma Inc realized cash outflow of $ -0.2per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.
Kinnate Biopharma Inc Price to Book Ratio is at 0.72 lower than Industry Avg. of 77.28. and higher than S&P 500 Avg. of 0.01
• More on KNTE's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com